Overview

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Status:
NOT_YET_RECRUITING
Trial end date:
2030-03-05
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
Phase:
PHASE1
Details
Lead Sponsor:
Hoffmann-La Roche